Androgenetic alopecia is a common condition, with severe attendant psychosocial implications, and for which it is difficult to obtain a satisfactory degree of clinical improvement.
To explore the possible clinical benefit of injecting platelet-derived growth factors into the scalp of patients using a specific autologous blood concentrate.
Two injections of a leukocyte platelet–rich plasma (L-PRP) with the addition of concentrated plasmatic proteins were administered at baseline and after 3 months (single spin at baseline and double-spin centrifugation at 3 months). Macrophotographs were taken at baseline and after 6 months, and 2 independent evaluators rated them using Jaeschke rating of clinical change.
Sixty-four consecutive patients were enrolled. Some improvement was seen in all patients by 1 evaluator and in 62 by the other. The mean change in clinical rating was 3.2 (95% confidence interval [CI], 2.9–3.5) and 3.9 (95% CI, 3.5–4.3), and the proportion of patients reaching a clinically important difference was 40.6% and 54.7%, according to the 2 evaluators, respectively.
Our pilot study may provide preliminary evidence that this treatment may induce some degree of clinical advantage for male- and female-pattern baldness. This may warrant the design of randomized controlled clinical trials to formally test this procedure.
*Plastic Surgery and Regenerative Surgery Unit, IDI-IRCCS, Rome, Italy;
†Second Clinical Dermatology Unit, IDI-IRCCS, Rome, Italy;
‡Hair Restoration Surgery, Greco Medical Group, Sarasota, Florida;
§Health Services Research Unit, IDI-IRCCS, Rome, Italy
Address correspondence and reprint requests to: Damiano Abeni, MD, MPH, Health Services Research Unit, IDI-IRCCS, via dei Monti di Creta, 104, 00167 Rome, Italy, or e-mail: firstname.lastname@example.org
Supported in part (D.A.) by the “Progetto Ricerca Corrente 2012 and 2013” of the Italian Ministry of Health.
The authors have indicated no significant interest with commercial supporters.